From the CEO
Our vision at Pluristem Therapeutics is to leverage our position as a global leader in placenta-based cell science to become the world’s leader in developing and manufacturing cell therapy products. We believe our cutting edge technology can produce therapies that will become the standard of care for treating a host of inflammatory and ischemic conditions. We also believe “the process is the product.” This reflects our view that precise control of the entire process, from obtaining cells from the source, to delivery to the patient, is vital to the success of a cell therapy product. Our fully automated process, proprietary 3D cell expansion technology and increasing knowledge of the placental cell drive us towards the development of additional product candidates for new indications and markets.
On July 23 we hosted a Key Opinion Leader breakfast in New York. Dr. Baha Sibai, a world renowned expert in preeclampsia, Director of the Maternal-Fetal Medicine Fellowship Program and a Professor in the Department of Obstetrics and Gynecology at University of Texas Health Science Center, spoke about this serious complication of pregnancy, its heavy costs to society, and the potential of cell therapy to treat it. This tremendous unmet medical need makes this indication one of our top priorities at Pluristem and we are hopeful that the strong preclinical data we have accumulated using PLX-PAD in preeclampsia will translate into similar results in the clinic. If you would like to learn more about preeclampsia and Pluristem’s preeclampsia program, the recording of the webcast from the KOL event is above.
Chairman and CEO